🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

342 results for “Novartis Pharmaceuticals” Clear

  1. Study to evaluate the pharmacokinetics, safety and tolerability of Secukinumab in patients with GCA or PMR

    Novartis Pharmaceuticals

    Polymyalgia rheumatica (PMR), Giant cell arteritis (GCA)

    phase 1 other active

    1 trial

  2. -, IPTACOPAN, -, -, -

    Novartis Pharmaceuticals

    IgA Nephropathy

    approved small molecule active

    1 trial

  3. Aliskiren

    Novartis Pharmaceuticals

    Hypertension

    approved small molecule completed

    1 trial

  4. CERITINIB

    Novartis Pharmaceuticals

    non small cell lung cancer

    approved small molecule active

    1 trial

  5. Enteric-Coated Mycophenolate Sodium (EC-MPS)

    Novartis Pharmaceuticals

    Renal Transplant

    approved small molecule completed

    1 trial

  6. Fluvirin(TIVf)

    Novartis Pharmaceuticals

    Influenza

    approved mab completed

    1 trial

  7. INCLISIRAN SODIUM, BEMPEDOIC ACID, ATORVASTATIN, ROSUVASTATIN, EZETIMIBE

    Novartis Pharmaceuticals

    Hypercholesterolemia

    approved small molecule active

    1 trial

  8. IPTACOPAN HYDROCHLORIDE, IPTACOPAN

    Novartis Pharmaceuticals

    C3 Glomerulopathy or idiopathic immune-complex membranoproliferative glomerulonephritis

    approved small molecule active

    1 trial

  9. Indacaterol

    Novartis Pharmaceuticals

    Chronic Obstructive Pulmonary Disease

    approved small molecule completed

    1 trial

  10. Jakavi 5 mg tablets, Jakavi 10 mg tablets, Jakavi 15 mg tablets, Jakavi 20 mg tablets, Jakavi 5 mg tablets, HDM201, RUXOLITINIB, Jakavi 20 mg tablets, Farydak 15 mg hard capsules, Jakavi 10 mg tablets, Jakavi 15 mg tablets, Jakavi 5 mg tablets, Farydak 10 mg hard capsules, Jakavi 10 mg tablets, Jakavi 15 mg tablets, HDM201, Jakavi 20 mg tablets

    Novartis Pharmaceuticals

    This study is designed to accept patients with varied disease origins, depending on the parent protocol

    approved small molecule active

    1 trial

  11. Kesimpta 20 mg solution for injection in pre-filled syringe

    Novartis Pharmaceuticals

    Relapsing forms of Multiple Sclerosis (RMS)

    approved small molecule active

    1 trial

  12. LETROZOLE, RIBOCICLIB, GOSERELIN ACETATE, LEE011, TAMOXIFEN

    Novartis Pharmaceuticals

    HR+, HER2- advanced or metastatic breast cancer

    approved small molecule active

    1 trial

  13. Mekinist, DRB436, DRB436, TMT212, TMT212, Mekinist 0.5 mg film-coated tablets, DRB436, Mekinist 2 mg film-coated tablets

    Novartis Pharmaceuticals

    Children and Adolescents with Cancers Harboring V600 mutation.

    approved small molecule active

    1 trial

  14. Neovascular Age-related Macular Degeneration

    Novartis Pharmaceuticals

    Neovacular Age-related Macular Degeneration

    approved other completed

    1 trial

  15. Ofatumumab

    Novartis Pharmaceuticals

    Relapsing Multiple Sclerosis

    approved mab completed

    1 trial

  16. Placebo of vildagliptin

    Novartis Pharmaceuticals

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  17. Placebo to AIN457 150 mg/1 mL Solution for injection in pre-filled syringe, SECUKINUMAB

    Novartis Pharmaceuticals

    non-radiographic axial spondyloarthritis

    approved small molecule active

    1 trial

  18. Pluvicto 1 000 MBq/mL solution for injection/infusion

    Novartis Pharmaceuticals

    Prostate cancer

    approved small molecule active

    1 trial

  19. ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, ROSUVASTATIN, Placebo to KJX839 (Inclisiran sodium) 0 mg/1.5 mL solution for injection in pre-filled syringe, INCLISIRAN

    Novartis Pharmaceuticals

    Hypercholesterolemia

    approved small molecule active

    1 trial

  20. Ribociclib

    Novartis Pharmaceuticals

    Metastatic Breast Cancer

    approved small molecule active

    1 trial

  21. Rivastigmine

    Novartis Pharmaceuticals

    Alzheimer's Disease

    approved small molecule completed

    1 trial

  22. Rivastigmine transdermal patch

    Novartis Pharmaceuticals

    Alzheimer's Disease

    approved small molecule completed

    1 trial

  23. SEG101

    Novartis Pharmaceuticals

    Sickle cell disease

    approved small molecule active

    1 trial

  24. Secukinumab s.c. injection

    Novartis Pharmaceuticals

    Autoimmunity, Inflammation

    approved mab active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources